Detecting Anosognosia from the Prodromal Stage of Alzheimer's Disease.

Alzheimer’s disease HABC-M anosognosia assessment caregiver burden error-monitoring timely diagnosis

Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2023
Historique:
medline: 23 10 2023
pubmed: 18 9 2023
entrez: 18 9 2023
Statut: ppublish

Résumé

Though not originally developed for this purpose, the Healthy Aging Brain Care Monitor (HABC-M) seems a valuable instrument for assessing anosognosia in Alzheimer's disease (AD). Our study aimed at 1) investigating the validity of the HABC-M (31 items), and its cognitive, psychological, and functional subscales, in discriminating AD patients from controls; 2) exploring whether the HABC-M discrepancy scores between the self-reports of patients/controls in these different domains and the respective ratings provided by their caregivers/informants correlate with an online measure of self-awareness; 3) determining whether the caregiver burden level, also derived from the HABC-M, could add additional support for detecting anosognosia. The HABC-M was administered to 30 AD patients and 30 healthy controls, and to their caregivers/informants. A measure of online awareness was established from subjects' estimation of their performances in a computerized experiment. The HABC-M discrepancy scores distinguished AD patients from controls. The cognitive subscale discriminated the two groups from the prodromal AD stage, with an AUC of 0.88 [95% CI: 0.78;0.97]. Adding the caregiver burden level raised it to 0.94 [0.86;0.99]. Significant correlations between the HABC-M and online discrepancy scores were observed in the patients group, providing convergent validity of these methods. The cognitive HABC-M (six items) can detect anosognosia across the AD spectrum. The caregiver burden (four items) may corroborate the suspicion of anosognosia. The short-hybrid scale, built from these 10 items instead of the usual 31, showed the highest sensitivity for detecting anosognosia from the prodromal AD stage, which may further help with timely diagnosis.

Sections du résumé

BACKGROUND
Though not originally developed for this purpose, the Healthy Aging Brain Care Monitor (HABC-M) seems a valuable instrument for assessing anosognosia in Alzheimer's disease (AD).
OBJECTIVES
Our study aimed at 1) investigating the validity of the HABC-M (31 items), and its cognitive, psychological, and functional subscales, in discriminating AD patients from controls; 2) exploring whether the HABC-M discrepancy scores between the self-reports of patients/controls in these different domains and the respective ratings provided by their caregivers/informants correlate with an online measure of self-awareness; 3) determining whether the caregiver burden level, also derived from the HABC-M, could add additional support for detecting anosognosia.
METHODS
The HABC-M was administered to 30 AD patients and 30 healthy controls, and to their caregivers/informants. A measure of online awareness was established from subjects' estimation of their performances in a computerized experiment.
RESULTS
The HABC-M discrepancy scores distinguished AD patients from controls. The cognitive subscale discriminated the two groups from the prodromal AD stage, with an AUC of 0.88 [95% CI: 0.78;0.97]. Adding the caregiver burden level raised it to 0.94 [0.86;0.99]. Significant correlations between the HABC-M and online discrepancy scores were observed in the patients group, providing convergent validity of these methods.
CONCLUSIONS
The cognitive HABC-M (six items) can detect anosognosia across the AD spectrum. The caregiver burden (four items) may corroborate the suspicion of anosognosia. The short-hybrid scale, built from these 10 items instead of the usual 31, showed the highest sensitivity for detecting anosognosia from the prodromal AD stage, which may further help with timely diagnosis.

Identifiants

pubmed: 37718816
pii: JAD230552
doi: 10.3233/JAD-230552
pmc: PMC10578267
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1723-1733

Subventions

Organisme : NIA NIH HHS
ID : RF1 AG074204
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG079324
Pays : United States

Références

Int J Geriatr Psychiatry. 2016 Jul;31(7):799-808
pubmed: 26643996
Int J Geriatr Psychiatry. 2013 Mar;28(3):291-7
pubmed: 22555993
Br J Clin Psychol. 2004 Jun;43(Pt 2):177-196
pubmed: 15169617
Eur J Neurol. 2007 Apr;14(4):455-60
pubmed: 17388998
Cortex. 2014 Dec;61:5-8
pubmed: 25481462
Front Hum Neurosci. 2013 Dec 05;7:830
pubmed: 24367313
Front Psychiatry. 2021 Mar 31;12:631518
pubmed: 33868048
Cortex. 2007 Oct;43(7):1020-30
pubmed: 17941357
Int J Alzheimers Dis. 2011;2011:483897
pubmed: 21660200
J Alzheimers Dis. 2016 May 31;53(3):1133-43
pubmed: 27258415
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9
pubmed: 1627973
Neuropsychologia. 2011 Jul;49(9):2609-18
pubmed: 21620877
Neurology. 2018 Mar 13;90(11):e932-e939
pubmed: 29444971
Cortex. 2014 Dec;61:64-73
pubmed: 25481465
Alzheimer Dis Assoc Disord. 1996 Summer;10(2):68-76
pubmed: 8727167
Int J Geriatr Psychiatry. 2014 Aug;29(8):852-62
pubmed: 24753076
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Gerontologist. 1980 Dec;20(6):649-55
pubmed: 7203086
Front Hum Neurosci. 2020 Jan 09;13:453
pubmed: 31998101
Alzheimers Dement (Amst). 2020 Sep 30;12(1):e12079
pubmed: 33024810
Clin Interv Aging. 2012;7:143-57
pubmed: 22791987
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
J Int Neuropsychol Soc. 2010 May;16(3):463-73
pubmed: 20188013
J Geriatr Psychiatry Neurol. 2014 Sep;27(3):220-6
pubmed: 24700707
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):719-25
pubmed: 16549411
Curr Neurol Neurosci Rep. 2017 Mar;17(3):27
pubmed: 28283961
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Clin Interv Aging. 2014 Dec 05;9:2123-32
pubmed: 25584024
Cortex. 2023 Sep;166:428-440
pubmed: 37423786
J Alzheimers Dis. 2017;59(2):753-762
pubmed: 28671134
Alzheimer Dis Assoc Disord. 1999 Jul-Sep;13(3):151-6
pubmed: 10485574

Auteurs

Thomas Guieysse (T)

Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Roxane Lamothe (R)

Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Marion Houot (M)

Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Solofo Razafimahatratra (S)

Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Takfarinas Medani (T)

Signal & Image Processing Institute, University of Southern California, Los Angeles, CA, USA.

François-Xavier Lejeune (FX)

Paris Brain Institute (Institut du Cerveau, ICM), Data Analysis Core, INSERM, CNRS, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Pitié-Salpêtrière University Hospital, Paris, France.

Gérard Dreyfus (G)

ESPCI Paris - PSL, Paris, France.

André Klarsfeld (A)

Laboratory of Brain Plasticity, CNRS UMR 8249, ESPCI Paris - PSL, Paris, France.

Dimitrios Pantazis (D)

McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Etienne Koechlin (E)

Laboratoire de Neurosciences Cognitives et Computationnelles, École Normale Supérieure, Paris, France.

Katia Andrade (K)

Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
Laboratory of Brain Plasticity, CNRS UMR 8249, ESPCI Paris - PSL, Paris, France.
FrontLab, Paris Brain Institute, ICM, Pitié Salpêtrière GH, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH